首页> 美国卫生研究院文献>Journal of Kidney Cancer and VHL >Gramicidin A: A New Mission for an Old Antibiotic
【2h】

Gramicidin A: A New Mission for an Old Antibiotic

机译:Gramicidin A:旧抗生素的新使命

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gramicidin A (GA) is a channel-forming ionophore that renders biological membranes permeable to specific cations which disrupts cellular ionic homeostasis. It is a well-known antibiotic, however it’s potential as a therapeutic agent for cancer has not been widely evaluated. In two recently published studies, we showed that GA treatment is toxic to cell lines and tumor xenografts derived from renal cell carcinoma (RCC), a devastating disease that is highly resistant to conventional therapy. GA was found to possess the qualities of both a cytotoxic drug and a targeted angiogenesis inhibitor, and this combination significantly compromised RCC growth in vitro and in vivo. In this review, we summarize our recent research on GA, discuss the possible mechanisms whereby it exerts its anti-tumor effects, and share our perspectives on the future opportunities and challenges to the use of GA as a new anticancer agent.
机译:Gramicidin A(GA)是形成通道的离子载体,可使生物膜对特定阳离子具有渗透性,从而破坏细胞离子稳态。它是一种众所周知的抗生素,但作为癌症治疗剂的潜力尚未得到广泛评估。在最近发表的两项研究中,我们表明GA治疗对源自肾细胞癌(RCC)的细胞系和肿瘤异种移植物有毒,肾细胞癌是对常规疗法高度耐药的毁灭性疾病。发现GA具有细胞毒性药物和靶向血管生成抑制剂的特性,并且该组合显着损害了体外和体内RCC的生长。在这篇综述中,我们总结了我们最近对GA的研究,讨论了其发挥其抗肿瘤作用的可能机制,并就使用GA作为新型抗癌药的未来机遇和挑战分享了我们的观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号